Ephedrine Sulfate Injection
NDC Package 68083-495-25
Package Information
Ephedrine Sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. . This formulation utilizes a injection delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-495 and is authorized under FDA application ANDA216146.
Identification & Billing
- RxCUI: 1116294 - ePHEDrine sulfate 50 MG in 1 ML Injection
- RxCUI: 1116294 - 1 ML ephedrine sulfate 50 MG/ML Injection
- RxCUI: 1116294 - ephedrine sulfate 50 MG per 1 ML Injection
Clinical Specifications
- Adrenergic alpha-Agonists - [MoA] (Mechanism of Action)
- Adrenergic beta-Agonists - [MoA] (Mechanism of Action)
- Increased Norepinephrine Activity - [PE] (Physiologic Effect)
- Norepinephrine Releasing Agent - [EPC] (Established Pharmacologic Class)
- alpha-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
- beta-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-495 - Ephedrine Sulfate
- 68083-495-25 - 25 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE
- 68083-495 - Ephedrine Sulfate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-495-25 identifies a specific commercial package of 25 vial, single-dose in 1 carton / 1 ml in 1 vial, single-dose of Ephedrine Sulfate, a human prescription drug labeled by Gland Pharma Limited. This injection is formulated for intravenous use and contains ephedrine sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on February 25, 2022. The current certification is valid through December 31, 2026.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083049525. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.